Sarcoma

Clinical trials for patients with cancer of the soft tissue or bone. This includes deep skin tissue, blood vessels, nerves, muscle, fat, bone and cartilage.

If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information. 

For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.

Clinical Trials Enquiry Coordinator

Business hours, Mon to Friday between 9am - 2pm
Email [email protected]
Phone (03) 8559 7456

Open and Recruiting Clinical Trials

A clinical trial to test if the treatment Pembrolizumab given with Radiotherapy is better than Radiotherapy given alone in patients with soft tissue sarcoma of the arm or leg

Cancer type

Soft tissue sarcoma of the arm or leg

Status

Open and recruiting

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.

Brief summary

A clinical trial to test if the treatment Pembrolizumab given with radiotherapy is better than radiotherapy alone in patients with soft tissue sarcoma that are at high risk of coming back or spreading to other parts of the body. Pembrolizumab is a type of treatment called immunotherapy, which works with your immune system to help stop cancer cells growing.

Who can participate

Patients who:

  • Have high risk of the cancer coming back or spreading to other parts of the body

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. 

A clinical trial to test three chemotherapy combinations in patients with ewing sarcoma to see which is the best and has less side effects

Cancer type

Ewing Sarcoma

Status

Open and recruiting

Phase

Two/three: A phase two and three clinical trial is tested in a larger group of patients with specific cancer types and compares new treatment to standard treatment that are already available for a cancer type.  A Phase two/three will also focus on learning more about the safety and side effects of the new treatment.

Brief summary

The aim of the clinical trial is to find the best chemotherapy combination for patients with Ewing Sarcoma that has come back or not responded to previous treatment. All treatment are currently available but have never been compared in a clinical trial to test which is the best and has less side effects. Patients will be randomly selected to receive one of the following:

Arm 1: Six cycles of Topotecan and Cyclophosphamide

Arm 2: Six cycles of Irinotecan and Temozolomide

Arm 3: Four cycles of Ifosfamide

Patients will not know which treatment they are given.   

Who can participate

Patients who:

  • Have cancer that has come back or not responded to previous treatment
  • Have cancer that has spread to other parts of the body
  • Are able to have chemotherapy

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. 

A clinical trial to test the safety and effectiveness of the treatment Ramucirumab in pediatric and young adult patients with synovial sarcoma and desmoplastic small round cell cancer

Cancer type

Synovial sarcoma and desmoplastic small round cell cancer

Status

Open and recruiting

Phase

One/two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two test for the new treatment to find the best dose and find effective in these cancer types.

Brief summary

The clinical trial to test the safety and effectiveness of the treatment Ramucirumab given with Gemcitabine and Docetaxel (types of chemotherapy) for patients with synovial sarcoma and desmoplastic small round cell cancer who have received treatment for their cancer but it has gotten worse or have not responded to treatment given for their cancer. Ramucirumab works by reducing the blood supply to the cancer, slowing the growth of the cancer.

Patients with synovial sarcoma will receive either of the following:

Arm 1: Ramucirumab given with gemcitabine and docetaxel

Arm 2: Gemcitabine given with docetaxel

Patients with desmoplastic small round cell tumour receive either of the following:

Arm 1: Ramucirumab given with cyclophosphamide and vinorelbine therapy

Arm 2: Cyclosphamide given with vinorelbine

Who can participate

Patients who:

  • Have received treatment for their cancer but it has gotten worse or have not responded to treatment given for their cancer

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test the safety and effectiveness of the new treatment DCC-3014 in patients with tenosynovial giant cell tumours

Cancer Type

Tenosynovial giant cell tumours

Status

Open and recruiting

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.

Brief summary

A clinical trial to test the safety and effectiveness of DCC-3014 in patients with with tenosynovial giant cell tumours a type of sarcoma. DCC-3014 works by stopping changes in specific genes that contribute to cancer growth.

Who can participate

Patients who:

  • Have cancer that cannot be removed by surgery
  • Have symptoms because of the cancer

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test the safety and effectiveness of the new treatment BGB-290 (Pamiparib) given with Temozolomide in patients with soft-tissue sarcomas

Cancer type

Soft tissue sarcoma

Status

Opening soon

Phase

Phase 1: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

A clinical trial to test the safety and effectiveness of the treatment Pamiparib given in combination with Temozolomide. Pamiparib is a type of treatment called PARP inhibitor, which works by stopping PARP proteins from repairing the DNA of cancer cells, Temozolomide works by damaging cancer cells to prevent the cancer from growing. The aim the treatment combination is to shrink the cancer or stop the cancer from growing. Both treatments are given orally by mouth.

Who can participate

Patients who:

  • Have cancer has grown outside the body part it started in but has not yet spread to other parts of the body or
  • Have cancer that has spread to other parts of the body
  • Have not been treated for their cancer

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.